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Flavin-containing monooxygenase 3 (FMO3) is a polymorphic drug metabolizing enzyme 
associated with the genetic disorder trimethylaminuria. We phenotyped a white Argentinian 
11-year-old girl by medical sensory evaluation. After pedigree analysis with her brother and 
parents, this proband showed to harbor a new allele p.(P73L;E158K;E308G) FMO3 in trans 
configuration with the second new one p.(F140S) FMO3. Recombinant FMO3 proteins of the 
wild-type and the novel two variants underwent kinetic analyses of their trimethylamine N-
oxygenation activities. P73L;E158K;E308G and F140S FMO3 proteins exhibited moderately 
and severely decreased trimethylamine N-oxygenation capacities (~50% and ~10% of wild-
type FMO3, respectively). Amino acids P73 and F140 were located on the outer surface 
region in a crystallographic structure recently reported of a FMO3 analog. Changes in these 
positions would indirectly impact on key FAD-binding residues. This is the first report and 
characterization of a patient of fish odor syndrome caused by genetic aberrations leading to 
impaired FMO3-dependent N-oxygenation of trimethylamine found in the Argentinian 
population. We found novel structural determinants of FAD-binding domains, expanding the 
list of known disease-causing mutations of FMO3. Our results suggest that individuals 
homozygous for any of these new variants would develop a severe form of this disorder. 
 





Flavin-containing monooxygenases (FMOs) belong to a family of well conserved enzymes 
that are present in all living beings [1]. These monooxygenases are protecting enzymes that 
catalyze the N-oxygenation of a variety of nucleophilic organic nitrogen and sulfur 
compounds present in many drugs, pesticides, dietary components and other foreign 
compounds [2, 3]. To date, five functional FMO genes (FMO1-FMO5) and six pseudogenes 
(FMO6P-FMO11P) have been identified in humans [4, 5]. From these, FMO1, FMO3 and 
FMO5 are reportedly relevant to hepatic function [2, 3, 6]. The developmental maturation 
of FMO5 still remains controversial [7]. FMO1 is highly expressed during the fetal period and 
progressively decreases to undetectable levels after birth. By contrast, FMO3 expression 
onsets at the time of birth and increases over time, reaching an adult level during 
adolescence [8]. Crystal structures for analogs of vertebrate FMOs were recently described 
[9]. All FMOs enzymes, from bacteria to vertebrates, are dimers [9-11] but only the 
mammalian versions are ER anchored-membrane proteins due to an additional 
transmembrane α-helix domain [9]. FAD and NADPH binding sites are located deep into the 
structure of the protein [9]. The substrates have to navigate through protein tunnels to 
reach the catalytic area. Most residues in the active site and the cofactor binding-domain 
are conserved among a wide range of phyla [9-12]. Mutations in several of these residues 
affect the catalytic activity of the enzyme [12]. 
More than 30 different mutations and around 40 polymorphisms of hFMO3 have been 
reported so far [13]. Many of these have been associated with a metabolic disorder known 
as trimethylaminuria (TMAU) [14, 15]. TMAU or “fish odor syndrome” is a non-life-
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threatening condition arising from the altered or incomplete expression of the FMO3 
isoform. Under this condition, the volatile trimethylamine derived from dietary intake or 
produced by normal gut flora, typically with a decaying fish-like smell, is unable to be 
converted into the non-odorous trimethylamine N-oxide. Trimethylamine accumulation is 
then excreted through sweat, urine, breath and other body fluids [16, 17]. 
 The impaired polymorphic variants of FMO3 responsible for TMAU have been mainly 
determined [18]. Genetic testing is a useful tool to understand the molecular basis of the 
condition and to detect heterozygous carriers.  In this report, we describe a case of a white 
Argentinian 11-year-old girl undergoing progressive body malodor. TMAU was suspected 
and genetic testing was performed in all family members. To our knowledge, there are no 
previous published reports on TMAU genetic characterization in the Argentinian population. 
 
2. Materials and methods 
2.1 Ethics statement 
Written informed consent for genetic explorations and the authorization for publication of 
the results of this study were obtained from the patient and her family in Instituto de 
Investigaciones Bioquímicas de Bahía Blanca. This study was conducted under the approval 
by the ethics committee of Showa Pharmaceutcal University in accordance with the 
Declaration of Helsinki. 
2.2 Molecular analyses 
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FMO3 gene was sequenced and screened for mutations in the proband and her direct family 
members. Genomic DNA of all the concerned individuals was obtained from jaw swabs using 
the commercial kit DNA Puriprep S-kit (Inbio Highway). All of the FMO3 coding exons (i.e. 
exons 2 to 9) were amplified from genomic DNA by polymerase chain reaction (PCR) using 
the primer pairs shown in Table 1. PCR products were separated in agarose gels and DNA 
was extracted and purified using a commercial kit (PB-L). Purified DNA was sequenced using 
an external service (Macrogen Inc., Korea). To ensure fidelity, readings were performed on 
both directions. DNA alignments and polymorphism detection were carried out online using 
the Blast application at the NCBI website as well as other software programs (i.e. 
SnapGene). The sequence of the complete human FMO3 gene described in GenBank 
(Accession Number NG_012690.1) was used as reference. 
2.3 DNA constructs and heterologous expression  
Wild-type and variant FMO3 cDNAs were prepared as previously described [19]. Site-
directed mutagenesis was carried out using a QuikChange II Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA, USA) to prepare the following variant FMO3 proteins. Wild-type 
and modified FMO3 cDNAs were introduced into the pTrc99A expression vector (Pharmacia 
Biotechnology, Milwaukee, MI, USA) and then transformed into Escherichia coli strain 
JM109, as described previously [19]. The entire coding regions of the wild-type and 
mutagenized FMO3 cDNAs were verified by resequencing both strands with specific 
primers (Table 1). Bacterial membrane fractions expressing FMO3 were prepared from 
bacterial pellets after centrifugation as previously described [19]. The amounts of 
recombinant FMO3 (0.012–0.16 nmol FMO3/mg bacterial protein) were determined by 
immunochemical quantification using an anti-FMO3 antibody (ab126790, Abcam, 
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Cambridge, UK) and comparing the results with those of a recombinant human FMO3 
standard (Corning), as reported previously [19].  
2.4 Enzyme functional assays 
Trimethylamine N-oxygenation rates were evaluated as described previously [19]. Briefly, a 
typical incubation mixture consisted of bacterial membranes (10 pmol equivalent FMO3) 
fortified with an NADPH-generating system (0.25 mM NADP
+
, 2.5 mM glucose 6-phosphate, 
and 0.25 units/mL glucose 6-phosphate dehydrogenase) and 0–1000 µM trimethylamine in 
a final volume of 0.10 mL of 50 mM potassium phosphate buffer (pH 8.4, [20]). Incubations 
were carried out at 37°C for 10 min and terminated. Product formation was found to be 
linear up to 20 pmol of all FMO3 proteins and for 20 min. Deuterium-labeled 
trimethylamine-d9 and trimethylamine N-oxide-d9 were used as internal standards. After 
centrifugation (4°C, 20,000 × g, 10 min), metabolite concentrations in the transferred 
supernatants were determined using liquid chromatography/tandem mass spectrometry 
[21]. The detection limit of trimethylamine N-oxide was 10 nM under the present conditions. 
Kinetic analyses of N-oxygenation of trimethylamine mediated by recombinant human 
FMO3 proteins were carried out in a nonlinear regression analysis using Prism software 
(GraphPad Software, San Diego, CA, USA). 
2.5. Structural analysis of human FMO3 
For the structural analysis of the enzyme we used the recently reported crystallographic 
dimer of AncFMO3-6 protein (PDB 6SE3) as a model for human FMO3 [9]. We analyzed 
molecular interactions and residue positions using the Discovery Studio Visualizer Client 





3.1. Case description. The proband is an Argentinian girl, that was 11 years old at the time 
of the first consultation to the physician. Her mother reported the girl produced increasingly 
body malodor, especially after the intake of choline-rich meals such as eggs, red meat, fish 
and milk, among others. The situation became a strong cause of social stress, isolation and 
suffering for the girl. The patient is the first child of healthy, unrelated parents; and her 
brother, 2 years younger, is apparently healthy. All the hematological parameters and 
biochemical indexes for renal, thyroid and liver function were within the normal range. The 
medical history of the patient showed that she underwent surgery for a thyroglossal duct 
cyst at the age of 9 month. She also presented an episode of atopic dermatitis. 
TMAU was suspected and nutritional treatment was implemented immediately with 
restriction of choline-rich foods. This intervention greatly improved the main clinical 
symptom by reducing body malodor. Additionally, a genetic test was recommended to 
check out the presence of mutations in her FMO3 gene. Trimethylamine levels in urine were 
not measured for two reasons, first, because these determinations are not available among 
the routine clinical laboratory techniques in Argentina and, second, the family did not 
authorize the study since an overdose of choline-rich foods in her diet would expose her to 
a strong distressing situation.  
3.2 Gene analysis of the proband. Exon analysis of the FMO3 gene in the proband revealed 
the presence of two polymorphisms already reported in the literature: 
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NG_012690.1:g.21949 G>A p.(E158K) in exon 4, resulting in a glutamic acid to lysine 
exchange (rs2266782) and NG_012690.1:g.28225 A>G p.(E308G) in exon 7, resulting in a 
glutamic acid to glycine exchange (rs2266780) (Fig. 1A). Additionally, the proband carried 
two unreported variations: NG_012690.1:g.17994 C>T p.(P73L) in exon 3, resulting in a 
proline to leucine substitution and NG_012690.1:g.21896 T>C p.(F140S) in exon 4, resulting 
in a phenylalanine to serine substitution (Fig. 1B). The proband resulted heterozygous for all 
the detected changes. 
3.3 Pedigree analysis. In order to study the genetic status of the proband relatives and the 
putative origin of her genetic configuration, the FMO3 genes of her brother and parents 
were evaluated. The analysis of the mother DNA revealed that she was carrying the newly 
detected mutation p.(P73L) in exon 3, plus the p.(E158K) and the p.(E308G) substitutions in 
exons 3 and 4, respectively. All changes were heterozygous. In consequence, substitution 
p.(P73L) was in cis configuration with p.(E158K) and p.(E308G) (Fig. 2). Examination of the 
father DNA showed that he was carrying the p.(F140S) substitution in exon 4 in 
heterozygosity with a wild allele (Fig. 2). Finally, her brother did not show any variations in 
his FMO3 gene sequence. Thus, pedigree analysis of the proband revealed that the new 
allele p.(P73L;E158K;E308G) FMO3 was in trans configuration with the second new allele, 
p.(F140S) FMO3. Therefore, she was a compound heterozygous for the two new alleles (Fig. 
2). 
3.4 In vitro FMO3 activity of the detected polymorphisms. Since the proband was the only 
member of the family that manifested a TMAU-like phenotype and in order to understand 
the contribution of each new FMO3 allele to the catalytic function, we analyzed the 
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activities of the recombinant enzymes carrying the detected variants. The new 
p.(P73L;E158K;E308G) and p.(F140S) FMO3 proteins were separately expressed in bacterial 
membranes. As shown in Fig. 3A, the amounts of recombinant two FMO3 variants (0.012 
nmol FMO3/mg bacterial protein) were ~one tenth of that of FMO3 wild-type (0.16 nmol 
FMO3/mg bacterial protein) determined by immunochemical quantification. Under the 
present condition, wild-type FMO3 showed Kcat and Km values of 54 ± 2 nmol/min/nmol 




 of kcat/Km value; Fig. 3B). The FMO3 variants 
resulting from the combination of P73L;E158K;E308G and of F140S showed Kcat and Km 




 of kcat/Km) and  





kcat/Km), respectively (Fig, 3B).  
3.5 Structure-function correlation. To get insights into the molecular consequences of P73L 
and F140S substitutions, we analyzed residue positions and interactions in the protein 
structure. We used the recently reported crystal structure of AncFMO3-6 (PDB 6SE3), as it 
was recently proposed as a structural model for human FMO3 [22]. None of the changed 
residues can directly interact with ligands or participate in the active site (Fig. 4A). Besides 
they do not participate in the dimerization domain (inner face of the monomer). Additional 
substitutions observed in one allele (E158K, E308G) are neither close to P73 position, 
suggesting independent structural alterations of the protein. All these four residues are 
exposed to the outer protein surface and far from the membrane-protein interface (Fig. 4A).  
In order to understand the structural alterations that these mutations could potentially 
introduce, we closer studied the molecular interactions of these residues. P73 is placed in a 
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random structure that connects α-helix 3 and 4, facing the outer surface of the protein. This 
residue is located outside the active site, just behind the isoalloxazine ring of FAD. It is 
surrounded by α-helix 3, 4, 21 and 22 (Fig. 4B, left). Before the α-helix 3, there are two 
residues that interact with the isoalloxazine ring, N61 (OD1 with FAD O4) and S62 (OG with 
FAD N3). Multiple hydrophobic interactions and one H-bond are observed in this region that 
could link P73 with these two residues interacting with FAD, so far P73-T469, Y469-C68, 
C68-Y74, Y74-M67 and M67-S62 (Fig. 4B, right). Besides most of these residues establish 
several interactions with one or more other residues, as is the case for both Y. 
F140 is located in the 6
th
 β–sheet, being part of a hydrophobic core. Similar to 
Schizosaccharomyces pombe FMO (sFMO) [23], in the ancFMO3-6 model, this core is formed 
by an inner wall composed of a five-stranded parallel β-sheet and an outer wall which is 
structured by a three-stranded antiparallel β-sheet (Fig. 4C). The inner wall makes contact 
with N1’ and N6’ of the adenosine group of the FAD through V110 (equivalent to V138 that 
interacts with the adenosine group in sFMO) (Fig 4C). Phenyl group of F140 protrudes into 
the middle of the hydrophobic core (Fig. 4C). All the residues forming the core are aliphatic: 
A6, I8, T29, F31, V110, V113, W125, V127, T129, A138, F140, V143 and I145 (Fig. 4c, right).  
 
4. Discussion 
In this study, we evaluated an 11-year-old Argentinian girl with clinical suspicion of TMAU. 
Our molecular genetic studies revealed that she was heterozygous for four polymorphisms. 
Two of them, E158K and E308G, are relatively common SNPs, known to cause a mild 
11 
 
reduction in FMO3 enzymatic activity [14, 24-28]. Because her father carried the F140S 
mutation and the mother carried the P73L, E158K and E308G mutations, we deduced the 
proband is a compound heterozygote for the polymorphisms with mutations P73L, E158K 
and E308G in the cis configuration while the F140S is in the second allele. In consequence, 
the proband expresses enzyme dimers that could either be composed of two identical 
monomers p.(P73L;E158K;E308G) or p.(F140S), or a combination of both. In vitro expression 
of these alleles exhibited a reduced metabolic capacity by 50% and 90%, respectively, 
compared to the wild-type FMO3 (Fig. 3). Proband parents did not show a TMAU-like 
phenotype, since they carry a wild-type FMO3 allele which would guarantee the proper 
trimethylamine metabolization. 
Several studies have reported that the E158K polymorphism leads to a reduced FMO3 
catalytic activity, which appears to vary, depending on the substrate [29, 30]. Previous in 
vitro expression studies showed that the K158 mutant form of the protein is a poorer 
trimethylamine N-oxygenator than the E158 form. When this mutation is combined with the 
E308G mutation on the same allele, results in an even more pronounced effect on FMO3 
function. However this combination slightly decreases enzyme activity (about 25%) [18]. 
These two FMO3 mutations have a relative high frequency in European population (0.420 
for E158K and 0.217 for E308G)[18]. Additionally, we report here two novel mutations, P73L 
and F140S, each of them causing a strong decrease in enzyme activity when they were 
evaluated in heterologous expression (more than 90% for F140S and about 50% for P73L). In 
the case of the proband, by having a combination of two defective alleles, FMO3 activity 
would have, in the best case, a 50% decrease, with a probability of 0.25, according to dimer 
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assembly or a 90% decrease with the same probability. The combination of both alleles, 
with a probability of 0.5, would decrease the activity of the enzyme in between 50 to 90%.  
Taking into consideration the genetic analysis and the improvement of the 
symptomatology after attaching to a choline-free diet, TMAU is strongly suggested in the 
proband, despite not having had the chance to test her metabolic capacity. TMAU is 
classified into severe (<60%) or mild (60-90%) according to metabolic capacity defined as 
the ratio of trimethylamine N-oxide to total trimethylamine in urine [31, 32]. Clinical 
symptoms in the proband were very strong even with a small consumption of choline-rich 
foods, such as eggs or soy products. In accordance, the expected decreased in FMO3 activity 
will always be in the range of 50% or lower, so this patient could be classified into the 
severe form of TMAU. 
All classical TMAU-causing mutations target residues located either in the active site or in 
structurally relevant regions [23, 33]. Indeed, the residues that most reduce the activity of 
the enzyme are near the surface in the structure [12]. According to this, P73 and F140 are 
residues which are not located at the active site of FMO3, but close to the cofactor binding 
domain. P73 is not in direct contact with FAD but is part of a net residues that through 
hydrophobic and H-bond interactions, contact with the FAD molecule. Probably the change 
of a proline by leucine results in the alteration of the interaction-balance with FAD, 
decreasing enzyme activity. Similar consequences are observed for the P70 position. This 
residue is located in the same loop and the change P70L showed a ~50% decreased enzyme 
activity among Japanese population [34]. Besides, residues that participate in the 
interaction network between N61-S62 and P73 (Fig. 4), such as K64, E65, M66 are reported 
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to abolish enzyme activity [12]. F140 is located in a hydrophobic core that delimits the 
adenine binding-site of the FAD molecule, which interacts with adenine through V110 (V138 
in S. pombe) establishing two H-bond with it [22, 23], (Fig. 4C). We detected a mutation that 
changes a hydrophobic amino acid for a polar one (F140S). We speculate that this change 
may disrupt the non-polar core, and then, would alter the interactions with the adenosine 
ring of the cofactor FAD. Given that F140S generates a strong decrease in enzyme activity, 
our results show that interactions with adenosine ring, which do not participate in the active 
zone, could alter the optimal disposition of the isoalloxazine ring in the active site. To date, 
only one mutation (E32K) that also interacts with the adenosine ring, has been reported to 
abolish enzyme activity [35]. One mutation in this hydrophobic core was reported related to 
a TMAU case [36]. The hydrophobic core collectively seems to be important for proper 
orientation of the adenosine ring and its alteration may impair enzyme function.  
In conclusion, we report here two novel mutations of FMO3 which are involved in a strong 
decrease of its metabolic capacity. In the proband, the combination of these novel 
mutations affecting both alleles, as a compound heterozygous, leads her to develop a “Fish 
Odor Syndrome”. FMO3 gene expression is expected to increase from childhood to puberty, 
worsening fish odor production [37], as is the case of the patient reported here. Due to the 
impossibility to measure trimethylamine levels in urine, we can only infer that the proband 
shows a TMAU-like syndrome, because she presents body malodor and mutations in FMO3 
gene that drastically impair enzymatic function. The case is the first reported in Argentina. 
The fact that urine trimethylamine determinations are not routinely performed in clinical 
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laboratories in Argentina, contributes to the relative underestimation of TMAU in this 
country.  
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Table 1. Primer pairs employed in PCR analysis (5’→3’). 
Target forward  reverse 
Exon 2 GGGATTACAGGCGTGAGCTA GCCATGGTAGCAGGTTTGGA 
Exon 3 GGTAACCACGGAGGTCCTGG GAGTTAGAGAGGCCACACTGTT 
Exon 4 GCACAAGAAATCATGCAGGG GACTTTAACAGAAGCGACCTTG 
Exon 5 TGCATCTATTCACAAGGTCGCT GATACCCTTCCCTCCTCCCC 
Exon 6 AGAGTAGAAGATGTTGGGTGAG CTCCCGGGACTAATTCCTGA 
Exon 7 TCCCAATGTTGCCTCCCATC GAGCTTTGGTGGTCTCAAG 
Exon 8 CCAATTCACCTCTGTTTGGC GAGGCATGGAGGGCTAAAACT 






Figure 1: Nucleotide sequences of novel FMO3 variants in the proband. Novel (A) and 
reported (B) changes in DNA sequences found in the proband. The sequences are shown 
only for sense strands of genomic DNA. The sequence of the complete human FMO3 gene 
described in GenBank (Accession Number NG_012690.1) was used as the reference. 
Figure 2. Pedigree analysis for the presence of detected FMO3 variants in proband’s 
family. Pedigree of the child with trimethylaminuria-like phenotype and FMO3 haplotype 
analysis of the family. The FMO3 gene sequence from GeneBank accession number 
NG_012690.1 was used as a reference sequence. 
Figure 3. Trimethylamine N-oxygenation activities mediated by recombinant wild-type and 
variant FMO3 proteins. (A) Recombinant wild-type, P73L;E158K;E308G, and F140S variant 
FMO3 proteins expressed in bacterial membranes are shown in lanes 1–3 and 8-10 (0.25, 
0.50 and 1.0 µg), 4–6 (2.5, 5.0 and 10 µg),  and 11–13 (2.5, 5.0 and 10 µg), respectively. 
Lanes 7 and 14 show recombinant human FMO3 in insect cell microsomes commercially 
available (control, 0.125 pmol of FMO3). (B) Kinetic parameters for wild-type FMO3 (circles), 
P73L;E158K;E308G variant (triangles), and F140S variant (squares) were calculated from a 
fitted curve by non-linear regression (mean ± standard error, n = 8 points of substrate 
concentrations of 25–1000 μM) with Michaelis-Menten equations: v = Vmax [S]/(Km + [S]). 
Figure 4. Crystal structures of the AncFMO3-6 and localization of mutated residues. Panel 
A. Crystallographic dimer of AncFMO3-6 protein (PDB 6SE3) are shown [9]. The molecule 
depicting their structures is orientated as if they were sitting on the membrane (black 
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dashed line). Front view (left) and back view (right). In one of the monomers, ribbon 
representation and ball-and-stick model of FAD are visualized. E308 is shown in blue, E158 
in yellow, F140 in red and P73 in green and the cofactors FAD and NAD, in cyan and orange 
respectively. In the other monomer, the hydrophobic shape is visualized in white. Panel B. 
P73 location and surrounding structures. Left. Schematic representation of the area in which 
P73 (CPK configuration, green) is located in the small domain of FMO3. Interactions among 
residues are shown as dashed lines. α-helixes are represented as red tubular structures. 
Residues are represented as ball-and-stick: Y469 (blue), Y74 (violet), C68 (cyan), M67 
(brown), S62 (cyan) and N61 (gray). Right. Interactions of residues in the neighborhood of 
FAD in which P73 is located. Dashed lines indicate hydrophobic interactions. Residues are 
colored as in left. Panel C. Localization of F140 residue at the hydrophobic core in the big 
domain of FMO3. Left. Schematic visualization of the hydrophobic core composed by an 
outer wall, formed by 3 antiparallel β-sheets and an inner wall, formed by 5 parallel β-
sheets. F140 (arrow) is located at the end of the outer wall projecting its R-group to the 
center of the core. H-bonding interactions of V110 with FAD are shown (dashed lines). Right. 
Distribution of charge around the surface of the hydrophobic core with red, white and blue 
representing negative, neutral and positive, respectively. F140 (arrow) is depicted as stick 
model (green) inside the hydrophobic core.  
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